SuperworthCellectar Biosciences shares outstanding CLRB
Diluted shares outstanding, averaged over each quarter, from 2011.
- Latest quarter, to Jun 30, 2026
- 12.2M
- On a year earlier
- +660.3%
- more shares
Cellectar Biosciences had 12.2M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 660.3% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 4.1M | +193% |
| FY2024 | 1.4M | +179% |
| FY2023 | 500.8K | +52% |
| FY2022 | 328.7K | +61% |
| FY2021 | 203.7K | +107% |
| FY2020 | 98.5K | +215% |
| FY2019 | 31.3K | +80% |
| FY2018 | 17.4K | +204% |
| FY2017 | 5.7K | +128% |
| FY2016 | 2.5K | +774% |
| FY2015 | 286 | +13% |
| FY2014 | 252 | +164% |
| FY2013 | 96 | +26% |
| FY2012 | 76 | +51% |
| FY2011 | 50 | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 12.2M | +660% | |
| Q1 FY26 | 4.2M | +176% | |
| Q4 FY25 | 4.1M | +193% | |
| Q3 FY25 | 3.2M | +138% | |
| Q2 FY25 | 1.6M | +29% | |
| Q1 FY25 | 1.5M | +57% | |
| Q4 FY24 | 1.4M | +179% | |
| Q3 FY24 | 1.3M | +252% | |
| Q2 FY24 | 1.2M | +233% | |
| Q1 FY24 | 978.2K | +161% | |
| Q4 FY23 | 500.8K | +52% | |
| Q3 FY23 | 377K | +85% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Cellectar Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.